RxDoctor Payments DataLook up a doctor →

Robert Burnstein, MD

Psychiatry · Sterling Heights, MINPI 1295827350

Payments from drug & device makers

$17,716in general payments, 2019–2025

Across 645 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$6K
  • Validus Pharmaceuticals LLC$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Lundbeck LLC$1K
  • AbbVie$1K
  • Sunovion Pharmaceuticals Inc.$613
  • plus $6K from 29 others

What the payments were for

  • Speaking & faculty fees$6,00034%
  • Food & beverage$11,67866%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,716 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$94,452
Medicare patients
223
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide18$22,770
Duloxetine Hcl225$5,701
Quetiapine Fumarate311$5,646
Trazodone Hcl409$5,460
Gabapentin332$4,807
AzstarysSerdexmethylphen/Dexmethylphen11$4,426
Lurasidone Hcl53$4,146
Bupropion Hcl SrBupropion Hcl186$3,628
Venlafaxine Hcl ErVenlafaxine Hcl108$3,460
Divalproex Sodium ErDivalproex Sodium51$3,287
Methylphenidate Hcl97$3,073
Fluphenazine Hcl13$3,064
Clozapine71$2,828
Olanzapine118$2,750
Oxcarbazepine72$2,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$412$22,77018 claims
Corium, LLCAzstarys$398$4,42611 claims
Lilly USA, LLCOlanzapine$14$2,750118 claims
Almatica Pharma LLCSertraline Hcl$64$1,992177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →